SAN FRANCISCO, CA—A new study from the Gladstone Institutes shows that a single drop of blood in the brain is sufficient to activate an autoimmune response akin to multiple sclerosis (MS).
SAN FRANCISCO, CA—Scientists from the Gladstone Institutes have discovered that salsalate, a drug used to treat rheumatoid arthritis, effectively reversed tau-related dysfunction in an animal model of frontotemporal dementia (FTD).
SAN FRANCISCO, CA—A new study from the Gladstone Institutes shows for the first time that impairments in mitochondria—the brain’s cellular power plants—can deplete cellular energy levels and cause neuronal dysfunction in a model of neurodegenerative disease.
SAN FRANCISCO, CA—The Gladstone Institutes announces the creation of Cure Network Ventures Inc. and Cure Network Dolby Acceleration Partners, LLC, a business endeavor with Dolby Family Ventures and Evotec AG, which will focus on Alzheimer’s disease.
SAN FRANCISCO—Scientists from the Gladstone Institutes and the University of Michigan have identified a cellular mechanism that can be targeted to treat ALS. The researchers revealed that increasing levels of a certain key protein successfully protected against cell death in both genetic and sporadic versions of the disease.
SAN FRANCISCO, CA—Scientists from the Gladstone Institutes and the University of California, San Francisco report in the Journal of Neuroscience that raising levels of the life-extending protein klotho can protect against learning and memory deficits in a mouse model of Alzheimer’s disease.
SAN FRANCISCO, CA—A study by scientists from the Gladstone Institutes shows that decreasing the number of A2A adenosine receptors in a particular type of brain cells called astrocytes improved memory in healthy mice.
SAN FRANCISCO, CA—Researchers at the Gladstone Institutes have shown that low levels of the protein progranulin in the brain can increase the formation of amyloid-beta plaques (a hallmark of Alzheimer’s disease), cause neuroinflammation, and worsen memory deficits in a mouse model of this condition.
SAN FRANCISCO, CA—Researchers at the Gladstone Institutes and University of California, San Francisco have shown that a loss of cells in the retina is one of the earliest signs of frontotemporal dementia (FTD) in people with a genetic risk for the disorder—even before any changes appear in their behavior.
SAN FRANCISCO, CA—Researchers at the Gladstone Institutes have shown that reducing brain levels of the protein tau effectively blocks the development of disease in a mouse model of Dravet syndrome, a severe intractable form of childhood epilepsy.